Cancer clinical trials in the region Auvergne-Rhône-Alpes

509 currently recruiting clinical trials
Region Auvergne-Rhône-Alpes

Phase 2 Brain tumors / Central nervous system tumors #NCT03970447 #2024-511452-40-00
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
1 2
Required previous treatments
Chemotherapy Radiotherapy
Excluded genetic anomalies
IDH1/2
Excluded previous treatments
Systemic Treatment-Naive Bevacizumab
3 recruiting sites
Global Coalition for Adaptive Research
Phase 2 Brain tumors / Central nervous system tumors #NCT03970447 #2024-511452-40-00
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
IDH1/2
Excluded previous treatments
Immunotherapy Chemotherapy Radiotherapy Radiochemotherapy
3 recruiting sites
Global Coalition for Adaptive Research
Phase 2 Brain tumors / Central nervous system tumors #NCT04945148 #2024-511026-31-01
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive Surgery
Excluded genetic anomalies
IDH1/2
5 recruiting sites
Hopital Foch
Phase 2 Lymphoma #NCT05463263
Required histologic types
B cell lymphoma T cell lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Step Pharma, SAS
Phase 2 Brain tumors / Central nervous system tumors #NCT02394626
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
1
Required previous treatments
Surgery Radiotherapy
8 recruiting sites
Insel Gruppe AG, University Hospital Bern
Phase 2 Lung cancer #NCT03175224 #2024-514542-37-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
EGFR MET
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded genetic anomalies
ALK BRAF KRAS G12C KRAS non G12C NTRK-1/2/3 RET ROS-1
5 recruiting sites
Apollomics
Phase 2 Lung cancer #NCT03175224 #2024-514542-37-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK BRAF EGFR KRAS G12C KRAS non G12C NTRK-1/2/3 RET ROS-1
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
5 recruiting sites
Apollomics
Phase 2 Lung cancer #NCT03175224 #2024-514542-37-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded genetic anomalies
ALK BRAF EGFR KRAS G12C KRAS non G12C NTRK-1/2/3 RET ROS-1
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
5 recruiting sites
Apollomics
Phase 2 Lung cancer #NCT03175224 #2024-514542-37-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded genetic anomalies
ALK BRAF EGFR KRAS G12C KRAS non G12C NTRK-1/2/3 RET ROS-1
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
5 recruiting sites
Apollomics
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT03175224 #2024-514542-37-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
BRAF EGFR KRAS G12C KRAS non G12C NTRK-1/2/3 RET ALK ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Targeted therapy
5 recruiting sites
Apollomics